NCT05232136View on ClinicalTrials.gov

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

October 31, 2025

Conditions
Non-muscle-invasive Bladder Cancer
Interventions
BIOLOGICAL

OH2 injection

OH2: Oncolytic Type 2 Herpes Simplex Virus

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Sponsors
All Listed Sponsors
lead

Binhui Biopharmaceutical Co., Ltd.

INDUSTRY